Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Resectable pancreatic small cell carcinoma.

Jordan M Winter¹, Amol K Narang, Aaron S Mansfield

¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD;

|April 6, 2011

Summary

Primary pancreatic small cell carcinoma (SCC) is rare. Surgical resection and adjuvant therapy, particularly cisplatin and etoposide, may improve survival rates for resectable pancreatic SCC patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and pathologic response of neoadjuvant pulsed electric field ablation and systemic therapy in early-stage resectable lung cancer: case series.

Journal of thoracic disease·2026

Same author

Reply to: "Beyond Response Rates: Interpreting Long-Term Benefit in CheckMate 743" and "Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743".

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026

Same author

Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Pancreas·2026

Same author

Identification of tumor-associated antigens with multi-cancer therapeutic potential.

Frontiers in immunology·2026

Same author

Amivantamab induces immune-mediated cytotoxicity in mesothelioma via EGFR and MET engagement.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Area of Science:

Oncology
Gastroenterology

Background:

Primary pancreatic small cell carcinoma (SCC) is an exceptionally rare malignancy.
Limited data exists on the prognosis and optimal treatment for resectable pancreatic SCC.

Observation:

This study reports on six patients with resectable pancreatic SCC from two institutions.
All patients underwent pancreaticoduodenectomy, and received adjuvant therapy, predominantly chemoradiation with cisplatin and etoposide.

Findings:

The median survival in this series was 20 months, significantly longer than previously reported for pancreatic SCC.
One patient achieved a record 173-month survival with chemoradiation, highlighting potential treatment efficacy.

Implications:

Pancreatic SCC, though rare, may have a better prognosis with surgical intervention and adjuvant therapy.

Keywords:

carcinoma pancreas resectable.small cell

Related Experiment Videos

Last Updated: Jun 3, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Cisplatin and etoposide-based chemotherapy, potentially combined with radiation, warrants further investigation for pancreatic SCC treatment.